Graft T-cell depletion as a prerequisite for the modulation of alloreactivity after haematopoietic stem cell transplantation

Transfusion Science

Volumn 18, Issue 2, 1997, Pages 327-336

  Tiberghien, Pierre ^a,b   Hervé, Patrick ^b   Cahn, Jean Yves ^b  

^a Immuno Molec Therapeut Laboratory   (France)

^b UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

ALLOIMMUNITY; BIOCOMPATIBILITY; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HLA TYPING; HUMAN; IMMUNOTHERAPY; LYMPHOCYTE DEPLETION; REVIEW; STEM CELL TRANSPLANTATION; T LYMPHOCYTE;

EID: 0347307447     PISSN: 09553886     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0955-3886(97)00023-4     Document Type: Article

References (67)

1. Sullivan KM: Graft versus host disease, in Forman SJ, Blume KG. Thomas ED (eds): Bone Marrow Transplantation. Oxford, Blackwell Scientific, 1994; 339-362.
2. Horrowitz MM, Gale RP, Sondel PM, et al.: Graft-versus-leukaemia reactions after bone marrow transplantation. Blood 1990; 75:555-562.
3. Antin JH: Graft-versus-leukaemia: no longer an epiphenomenon. Blood 1993; 82:2273-2277.
4. Biaise D, Gravis G, Maraninchi D: Long-term follow-up of T-cell depletion for bone marrow transplantation. Lancet 1994; 341:51-52.
5. Marmont AM, Horowitz MM, Gale RP, et al.: T-cell depletion of HLA-identical transplants in leukaemia. Blood 1991; 78: 2120-2130.
6. Wallny HJ, Rammensee HG: Identification of classical minor histocompatibility antigen as cell-derived peptide. Nature 1990; 343:275-278.
7. Schreuder GMT, Pool J, Blockland E, et al.: A genetic analysis of human minor histocompatibility antigen as cell-derived peptide. Nature 1990; 343:275-278.
8. Den Haan JMM, Scherman NE, Blockland E, et al.: Identification of a graft-versus-host disease-associated human minor histocompatibility antigen. Science 1995; 268:1476-1480.
9. Wang W, Meadows LR, Den Haan JMM, et al.: Human H-Y: a mal-specific histocompatibility antigen derived from the SMCY protein. Science 1995; 269:1588-1590.
10. De Brueger M, Bakker A, Van Rood JJ, Van der Woude F, Goulmy E: Tissue distribution of human minor histocompatibility antigens. Ubiquitous versus restricted tissue distribution indicates heterogeneity among human cytotoxic T-lymphocyte-defined non-MHC antigen, J Immunol 1992; 149:1788-1794.
11. Goulmy E, Schipper R, Pool J, et al.: Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation. N Engl J. Med 1996; 334:281-285.
12. Behar, E, Nelson, PhD, Chao, NJ, et al.:Polymorphism of adhesion molecule CD31 and its role in acute graft-versushost disease. N Engl Journal Med 1996; 334:286-291.
13. Maraninchi D, Biaise D, Rio B, et al.: Impact of T-cell depletion on outcome of allogeneic bone marrow transplantation for standard risk leukaemias. Lancet 1987; 2:175-178.
14. Biaise D, Gravis G, Maraninchi D: Long-term follow-up of T-cell depletion for bone marrow transplantation. Lancet 1994; 341:51-52.
15. Goldman JM, Gale RP, Horowitz MM, et al.: Bone marrow transplantation for chronic myelogenous leukaemia in chronic phase. Ann Intern Med 1988; 108:806-814.
16. Storb R, Deeg HJ, Whitehead J, et al.: Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukaemia. N Engl J Med 1986; 314:729-735.
17. Storb R, Deeg HJ, Pepe M, et al.: Methotrexate and cyclosporine versus cyclosporine alone for prophylaxis of graft-versus-host disease in patients given HLA-identical marrow grafts for leukaemia: long-term follow-up a controlled trial. Blood 1989; 73:1729-1734.
18. Reginald A, Clift C, Buckner CD, et al.: Allogenic marrow transplantation in patients with acute myeloid leukaemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76:1867-1871.
19. Bacigalupo A, Van Lint MT, Occini D, et al.: Increased risk of leukaemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukaemia. Blood 1991; 77:1423-1428.
20. Clift RA, Buckner CD, Appelbaum FR, et al.: Allogeneic marrow transplantation in patients with acute myeloid leukaemia in first remission: randomized trial of two irradiations regimens. Blood 1990; 76:1867-1871.
21. Antin JH, Ferrara JLM: Cytokine dysregulation and acute graft-versus-host disease. Blood 1992; 80:2964-2968.
22. Goldman J: Peripheral blood stem cells for allografting. Blood 1995; 85:1413-1415.
23. Korbling M: Allogeneic stem cell transplantation: the US experience. Hum Cell Ther 1996; 38:456-457.
24. Majolino I, Saglio G, Scimè R, et al.: High incidence of chronic GvHD after primary allogeneic peripheral blood stem cell transplantation in patients with haematologic malignancies. Bone Marrow Transplant 1996; 17:555-560.
25. Hartung H, Döcke WD, Gantner F, et al.: Effect of granulocyte colony-stimulating factor treatment on ex vivo blood cytokine response in human volunteers. Blood 1995; 85:2482-2489.
26. Pan L, Delmonte J, Jalonene CK, Ferrara JLM: Pre-treatment of donor mice with granulocyte colony-stimulating factor (G-CSF) polarizes donor T-lymphocytes toward type 2 cytokine production and reduces severity of experimental graft versus host disease. Blood 1995; 86:4422-4429.
27. Fowler DH, Kurasawa K, Smith R, Eckhaus MA, Gress RE: Donor CD4-enriched cells of Th2 cytokine phenotype regulate graft-versus-host disease without impairing allogeneic engraftment in sublethally irradiated mice. Blood 1994, 84:3540-3549.
28. Ushiyama C, Hirano T, Miyajima H, Okumura K, Ovary Z, Hashimoto H: Anti-IL-4 antibody prevents graft-versus-host disease in mice after bone marrow transplantation. J Immunol 1995; 154:2687-2696.
29. Marmont AM, Horowitz MM, Gale RP, et al.: T-cell depletion of HLA-identical transplants in leukaemia. Blood 1991; 78:2120-2130.
30. Reisner Y, Martelli MF: Bone marrow transplantation across HLA barriers by increasing the number of transplanted cells. Immunol Today 1995; 16:437-440.
31. Kernan NA, Young J, Papadopoulos E, et al.: Antithymocyte globulin (ATGAM) and methylprednisolone (MP) promote engraftment of T-cell depleted (SBA-E) BMTs from HLA-identical siblings. Blood 1995; 86(suppl 1): 621 a (abstr).
32. Zutter MM, Martin PJ, Sale GE: Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72:520-529.
33. Aversa F, Tabilio A, Terenzi A, et al.: Successful engraftment of T-cell-depleted haploidentical "three loci" incompatible transplants in leukaemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum. Blood 1984; 11:3948-3955.
34. Kaufman CL, Colson YL, Wren SM, Watkins S, Simmons RL, Ilstad ST: Phenotypic characterization of a novel bone-marrow-derived cell that facilitates engraftment of allogeneic bone marrow stem cells. Blood 1994; 84:2436-2446.
35. Schiltz KR, Paquet J, Bader S, Hayglass KT: Requirement for B cells and T-cell priming to minor histocompatibility antigens and development of graft-versus-host disease. Bone Marrow Transplant 1995; 16:289-295.
36. Cavazzano-Calvo M, Haddad E, Brockmeyer C, et al.: T and B cell ex vivo depletion of partially incompatible marrow graft. Bone Marrow Transplant 1996 (Suppl 1) S62 (abstr).
37. Beaujean F: Methods of CD34-positive cell separation: comparative analysis. Transfus Sci 1997;xx
38. Mavroudis D, Read E, Cottler-Fox M, et al.: CD34+ cell dose predicts survival, posttransplant morbidity, and rate of haematological malignancies. Blood 1996; 88:3223-3229.
39. Cavazzana-Calvo M, Fromont C, Le Deist, F, et al.: Specific elimination of alloreactive T-cells by an anti-interleukin-2 receptor B-chain specific immunotoxin. Transplantation 1990; 50:1-7.
40. Cavazzana-Calvo M, Stephan JL, Sarnacki S, et al.: Attenuation of graft-versus-host disease and graft rejection by ex vivo immunotoxin elimination of alloreactive T-cells in an H-2 haplotype disparate mouse combination. Blood 1994; 83:288-298.
41. Rencher SD, Houston JA, Lockey TD, Hurwitz JL: Eliminating graft-versus-host potential from T-cell immunotherapeutic populations. Bone Marrow Transplant 1996; 18:415-420.
42. Contassot E, Deschaseaux ML, Certoux JM, et al.: Retroviral-mediated transfer of herpes-simplex thymidine-kinase (HS-tk) gene in alloreactive T-lymphocytes. Blood, 1994;84:1403 (Abstr).
43. Van Gool SW, De Boer M, Ceuppens JL: The combination of anti-B7 monoclonal antibody and cyclosporin A induces alloantigen-specific anergy during a primary mixed lymphocyte reaction. J Exp Med 1994; 179:715-720.
44. Kernan NA, Collins NH, Juliano L, Caragena T, Dupont B, O'Reilly RJ: Clonable T-lymphocytes in T-cell depleted bone marrow transplants correlate with the development of GvHD. Blood 1986; 68:770-773.
45. Verdonck LF, Dekker AW, De Gast GC, Van Kempen ML, Lokhorst HM, Nieuwenhuis HK: Allogeneic bone marrow transplantation with a fixed low number of T-cells in the marrow graft. Blood 1994; 83:3090-3096.
46. Verdonck LF, Van Blockland WTM, Bosboom-Kalsbeek EK, Van Heugten HG, Tilanus MGJ, de Weger RA: Complete donor T-cell chimerism is accomplished in patients transplanted with bone marrow grafts containing a fixed low number of T-cells. Bone Marrow Transplant 1996; 18:389-395.
47. Brion A, Deconinck E, Racadot E, Tiberghien P, Hervé P, Cahn JY: Allogeneic transplantation with partial T-lymphocyte depletion: results of a pilot study of 21 patients. Hematol Cell Ther 1996; 38:111a (abstr).
48. Johnson BD, Truitt RL: Delayed infusions of immunocompetent donor cells after bone marrow transplantation breaks graft-versus-host tolerance and allows for persistent antileukemic reactivity without severe graft-versus-host disease. Blood 1996; 85:3302-3312.
49. Barrett AJ, Couriel D, Dunbar C, Fox M, Young NS, O'Kunnief P: Low incidence of acute GvHD following delayed T-cell add-back after T-depleted BMT for haematologic malignancies. Blood 1986; S1:619a (abstr).
50. Kolb H, Mittermuller J, Clemm C, et al.: Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukaemia in marrow transplant patients. Blood 1990; 76:2462-2465.
51. Van Rhee F, Lin F, Cullis JO, et al.: Relapse of chronic myeloid leukaemia after allogeneic bone marrow transplant: the case for giving donor leukocyte transfusions before the onset of haematologic relapse. Blood 1994; 83:3377-3383.
52. Mackinnon S, Barnett L, Heller G: Polymerase chain reaction is highly predictive of relapse in patients following T cell-depleted allogeneic bone marrow transplantation for chronic myeloid leukaemia. Bone Marrow Transplantation 1996; 17:643-647.
53. Rooney CM, Smith CA, Ng CYC, et al.: Use of modified virus-specific T-lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345:9-13.
54. Heslop HE, Ng CYC, Li C, et al.: Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus specific T-lymphocytes. Nature Med 1996; 2:551-555.
55. Papadopoulos EB, Ladanyi M, Emmanuel D, et al.: Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. N Engl J Med 1994; 330:1185-1191.
56. Walter EA, Greenberg PD, Gilbert MJ, et al.: Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med 1995; 333:1038-1044.
57. Tiberghien P: Use of suicide genes in gene therapy. J Leukocyte Bio 1994; 56:203-210.
58. Kit S, Leung WC, Jorgensen GN, Dubbs DR: Distinctive properties of thymidine kinase isozymes induced by human and avian herpes virus. Int J Cancer 1974; 14:598-610.
59. Tiberghien P, Reynolds CW, Keller, J, et al.: Ganciclovir treatment of herpes simplex kinase-transduced primary T-lymphocytes: an approach for specific in vivo donor T-cell depletion after bone marrow transplantation? Blood 1994; 84:1333-1341.
60. Tiberghien P, Cahn JY, Hervé P, et al.: Use of donor T-lymphocytes expressing herpes-simplex thymidine kinase in allogeneic bone marrow transplantation - a phase I study. Hum Gene Ther 1997; 8:615-624.
61. Tiberghien P, Cahn JY, Milpied N, et al.: Administration of donor T-cells expressing the herpes-simplex thymidine-kinase gene in conjunction with a T-cell depleted allogeneic marrow graft. Blood 1996; 88:1077 (Abstr).
62. Bonini C, Verzeletti S, Servida P, et al.: Transfer of the HSV-tk gene into donor peripheral blood lymphocytes for in vivo immunomodulation after allo-BMT. Blood 1994; 84 (suppl 1):110a (Abstr).
63. Bonini C, Verzeletti S, Zappone E, Rossini S, Traversari C, Bordignon C: Immunity against the transgene product may limit efficacy of HSV-tk-transduced donor peripheral blood lymphocytes after allo-BMT. Blood 1995; 86 (suppl 1):628a (abstr).
64. Nagler A, Ackerstein A, Or, R, et al.: Adoptive immunotherapy with mismatched allogeneic peripheral blood lymphocytes following autologous bone marrow transplantation. Exp Hematol 1992; 20:705a (abstr).
65. Tiberghien P, Delain M, Plouvier E, et al.: Allogeneic T-lymphocyte transfer ± IL-2 after autologous BMT for refractory hemopathies. 18th Annual Meeting of the European Bone Marrow Transplantation (EBMT), Stockholm, Sweden, 1992 (abstr).
66. Gallo G, Hallet MM, Gaschet J, et al.: Human HLA-specific T-cell clones with stable expression of a suicide gene: a possible tool to drive and control a graft-versus-host-graft-versus-leukaemia reaction? Blood 1996; 88:1098-1103.
67. Kline RM, Stiehm ER, Cowan MJ: Bone marrow "boosts" following T cell-depleted haploidentical bone marrow transplantation. Bone Marrow Transplant 1996; 17:543-548.